Abstract

The de novo L-cysteine biosynthetic pathway is critical for the growth, antioxidative stress defenses, and pathogenesis of bacterial and protozoan pathogens, such as Salmonella typhimurium and Entamoeba histolytica. This pathway involves two key enzymes, serine acetyltransferase (SAT) and cysteine synthase (CS), which are absent in mammals and therefore represent rational drug targets. The human parasite E. histolytica possesses three SAT and CS isozymes; however, the specific roles of individual isoforms and significance of such apparent redundancy remains unclear. In the present study, we generated E. histolytica cell lines in which CS and SAT expression was knocked down by transcriptional gene silencing. The strain in which CS1, 2 and 3 were simultaneously silenced and the SAT3 gene-silenced strain showed impaired growth when cultured in a cysteine lacking BI-S-33 medium, whereas silencing of SAT1 and SAT2 had no effects on growth. Combined transcriptomic and metabolomic analyses revealed that, CS and SAT3 are involved in S-methylcysteine/cysteine synthesis. Furthermore, silencing of the CS1-3 or SAT3 caused upregulation of various iron-sulfur flavoprotein genes. Taken together, these results provide the first direct evidence of the biological importance of SAT3 and CS isoforms in E. histolytica and justify the exploitation of these enzymes as potential drug targets.

Highlights

  • Critical metabolic pathways that are unique to pathogens and are significantly divergent from their hosts are rational targets for the development of new chemotherapeutic agents

  • We investigated the role of the cysteine biosynthesis pathway in E. histolytica using parasites in which genes for the enzymes involved in cysteine biosynthesis were silenced by antisense RNA-mediated transcriptional attenuation

  • The identification and functional characterization of the molecular components involved in essential metabolic pathways contribute to the overall understanding of parasite biology, and aid in the rational design of novel therapeutics

Read more

Summary

Introduction

Critical metabolic pathways that are unique to pathogens and are significantly divergent from their hosts are rational targets for the development of new chemotherapeutic agents. The cysteine biosynthetic pathway plays an important role in the incorporation of inorganic sulfur into organic compounds[1] and has been extensively studied in bacteria, plants, and protozoa[20,21,22,23,24]. In this pathway, SAT (EC 2.3.1.30) catalyzes the formation of O-acetyl-L-serine (OAS) from L-serine and acetyl-CoA15,16 (Fig. 1A). The sulfur-assimilatory cysteine biosynthetic pathway in plants, bacteria, and protozoa has been extensively studied and exploited for drug development, the role of individual SAT and CS isozymes and significance of the apparent redundancy of this pathway in E. histolytica remain to be elucidated. Using transcriptomic and metabolomic analyses, we demonstrated that EhCS and EhSAT3 are critical for SMC/

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.